Attorney Julie Myers Wood, chief executive of Guidepost Solutions, a compliance solutions company in Washington, D.C., said, given the seriousness of the nation's opioid crisis, she expects continued scrutiny of drug companies. (Photo: Shutterstock)
It is a fearsome time for general counsel and chief compliance officers at drug companies, as aggressive federal prosecutors are increasing scrutiny — as well as indictments — over their work.
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Sue Reisinger
Senior reporter at ALM since 2004; based in Florida; covers general counsel and white collar crime; contact: [email protected]
